Post-viral disorder

Summary

Post-viral disorder (MONDO:0021674) is a disease (an umbrella term covering 13 Mondo subtypes) and 2 clinical trials. Top therapeutic interventions include conestat alfa. A subtype of post-infectious disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 13 Mondo subtypes
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	post-viral disorder
Mondo ID	MONDO:0021674
SNOMED CT	123948009
UMLS	C1264605
MedGen	688821
Is cancer (heuristic)	no

Also known as: sequela of viral disease

Disease family

This is a subtype of post-infectious disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › post-infectious disorder › post-viral disorder

Related subtypes (13): encephalopathy, acute, infection-induced, infective urethral stricture, infectious otitis interna, otitis externa, infected hydrocele, Chagas cardiomyopathy, postinfectious vasculitis, postinfectious encephalitis, post-infectious syndrome, post-bacterial disorder, infection-related hemolytic uremic syndrome, infectious neuropathy, infection-induced acute-onset axonal neuropathy

Subtypes (13): oral hairy leukoplakia, Zika virus congenital syndrome, viral dilated cardiomyopathy, hepatitis C induced liver cirrhosis, herpes zoster, hepatitis D virus infection, immunodeficiency 32B, virus associated tumor, rubella encephalitis, AIDS dementia complex, post-infectious neuralgia, AIDS-related disorder, post-COVID-19 disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04705831	PHASE2	COMPLETED	Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
NCT04406584	Not specified	COMPLETED	Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CONESTAT ALFA	4	1